Applications for this meeting must be submitted by May 20, 2017. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
GRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above, any applicants who wish to be considered for an oral presentation should submit their application by March 17, 2017. Please refer to the application instructions in the Meeting Description section below for more details (if available).
The Gordon Research Seminar on Cancer Nanotechnology, held for the first time in 2017, will bring together graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.
Cancer nanotechnology is a complex
discipline that is fueled by the latest advances in basic chemistry and
biology. Translating fundamental science and innovative engineering solutions into new clinical options requires a coordinated effort of diverse group of of researchers. This unique forum will feature outstanding research by early career scientists across the continuum of cancer research.
The meeting will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS either by giving an oral presentation or presenting a poster. Therefore, all applications must include an abstract.
The Chairs will select speakers from abstracts submitted by March 17, 2017. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate, you must submit an application by the date indicated in the Application Deadline section above.
This GRS will be held in conjunction with the "Cancer Nanotechnology" Gordon Research Conference (GRC)
. Those interested in attending both meetings must submit an application for the GRC in addition to an application for the GRS. Refer to the associated GRC program page
for more information.
|2:00 pm - 5:00 pm||Arrival and Check-in|
|3:30 pm - 3:45 pm||Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair|
|3:45 pm - 4:30 pm||New Delivery Strategies for Anticancer Therapies|
|Discussion Leader: Nathan Gianneschi (University of California, San Diego, USA)|
|3:45 pm - 4:05 pm||Elizabeth Wayne (University of North Carolina at Chapel Hill, USA)|
"Macrophage-Mediated Gene Delivery to the Tumor Microenvironment"
|4:05 pm - 4:10 pm||Discussion|
|4:10 pm - 4:25 pm||Nitzan Krinsky (Technion - Israel Institute of Technology, Israel)|
"Protein-Producing Particles for On-Site Drug Delivery"
|4:25 pm - 4:30 pm||Discussion|
|4:30 pm - 6:00 pm||Poster Session|
|7:30 pm - 9:30 pm||New Anticancer Nanomaterials / Keynote Session: Spherical Nucleic Acids as a Powerful New Platform to Develop Cancer Vaccines|
|Discussion Leader: Emily Day (University of Delaware, USA)|
|7:30 pm - 7:50 pm||Sumit Dadhwal (University of Otago, New Zealand)|
"Bioorthogonal Triggered Responsive Polymersomes for Anticancer Drug Delivery"
|7:50 pm - 8:00 pm||Discussion|
|8:00 pm - 8:20 pm||Julius Mueller (Max Planck Institute for Polymer Research, Germany)|
"Controlling the Protein Corona of Nanoparticles by Coating Their Surface with Tunable Surfactants"
|8:20 pm - 8:30 pm||Discussion|
|8:30 pm - 9:10 pm||Chad Mirkin (Northwestern University, USA)|
"Spherical Nucleic Acids as a Powerful New Platform to Develop Cancer Vaccines"
|9:10 pm - 9:30 pm||Discussion|
|7:30 am - 8:30 am||Breakfast|
|9:00 am - 11:00 am||Cancer Nanomedicines: From Bench to Clinic|
|Discussion Leader: Kurt Breitenkamp (Exponent, Inc., USA)|
|9:00 am - 9:20 am||Anna Brown (Oregon State University, USA)|
"Radiation Dose Enhancing Nanoparticles: Designing for Efficacy"
|9:20 am - 9:30 am||Discussion|
|9:30 am - 9:50 am||Desiree Van Haute (U.S. Food and Drug Administration, USA)|
"Development of Robust Asymmetric Field Flow Fractionation Methods for the Comparison of Innovator and Generic Liposomal Nanomedicines in Oncology"
|9:50 am - 10:00 am||Discussion|
|10:00 am - 10:20 am||Weijia Wang (Moderna Therapeutics, USA)|
"Specific Delivery of mRNA to Tumors via Different Routes of Administrations"
|10:20 am - 10:30 am||Discussion|
|10:30 am - 10:50 am||Zvi Yaari (Technion - Israel Institute of Technology, Israel)|
"Theranostic Barcoded Nanoparticles for Personalized Cancer Medicine"
|10:50 am - 11:00 am||Discussion|
|11:00 am - 12:30 pm||Poster Session|
|Coffee will be served in the poster area from 11:00 am - 11:30 am|
|1:30 pm - 2:30 pm||Visualization and Modeling of Disease and Treatment Outcomes|
|Discussion Leader: Alexander Kislukhin (SomaLogic, USA)|
|1:30 pm - 1:50 pm||Stefan Wilhelm (University of Toronto, Canada)|
"Analysis of Nanoparticle Targeting to Solid Tumors"
|1:50 pm - 2:00 pm||Discussion|
|2:00 pm - 2:20 pm||Kim Tsoi (University of Toronto, Canada)|
"Mechanism of Hard Nanomaterial Clearance by the Liver"
|2:20 pm - 2:30 pm||Discussion|
|2:30 pm - 3:00 pm||Evaluation Period|
|Fill in GRS Evaluation Forms|
|3:00 pm||Seminar Concludes|
Funding for this conference was made possible (in part) by 1R13CA213845-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.